SGMO250117P4000
- 1.70
- 0.000.00%
Sangamo Therapeutics Newsroom
Jefferies Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $3
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Wells Fargo Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Cuts Target Price to $2
Sangamo Therapeutics Is Maintained at Buy by Jefferies
Jefferies Initiates Sangamo Therapeutics(SGMO.US) With Buy Rating, Announces Target Price $3
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
Sangamo Therapeutics Analyst Ratings
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $2 From $3, Keeps Equalweight Rating
Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Sangamo Therapeutics Analyst Ratings
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
Truist Financial Upgrades Sangamo Therapeutics(SGMO.US) to Buy Rating, Announces Target Price $7
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Is Maintained at Overweight by Barclays
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10